Cargando…
Case report: reinitiating pembrolizumab treatment after small bowel perforation
BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as paradigm shifting treatment options for a number of cancers. Six antibodies targeting the immune checkpoint proteins programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) or cytotoxic T-lymphocyte associated protein 4...
Autores principales: | Beck, Tim N., Kudinov, Alexander E., Dulaimi, Essel, Boumber, Yanis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482547/ https://www.ncbi.nlm.nih.gov/pubmed/31018834 http://dx.doi.org/10.1186/s12885-019-5577-5 |
Ejemplares similares
-
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019) -
Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer
por: Bychkov, Igor, et al.
Publicado: (2023) -
Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer
por: Bychkov, Igor, et al.
Publicado: (2023) -
Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
por: Makhov, Petr, et al.
Publicado: (2021) -
Phosphorylation of a reinitiation supporting protein, RISP, determines its function in translation reinitiation
por: Mancera-Martínez, Eder, et al.
Publicado: (2021)